Effects of Animal Strain, Dose, and Cotreatment with Saikosaponin b2 on the Pharmacokinetics of Saikosaponin a in Rats

  • Ruijia Fu
  • Jingjing Liu
  • Yunwen Xue
  • Zunjian Zhang
  • Rui SongEmail author
Short Communication


Background and Objectives

Radix Bupleuri (RB, Chaihu in Chinese) has been used as a traditional medicine for more than 2000 years in China, Japan, Korea, and other Asian countries. Saikosaponin a (SSa), the most abundant saikosaponin in RB, exhibits various pharmacological activities, including anti-inflammatory, antitumor, antiviral, immunoregulatory, neuromodulatory, and hepatoprotective activities. A comprehensive study of the pharmacokinetic characteristics of SSa is needed to gain a detailed understanding of its pharmacodynamic mechanism.


Here, we determined the effects of rat strain (Sprague Dawley and Wistar), oral dose, and cotreatment with saikosaponin b2 (SSb2) on the pharmacokinetics of SSa by measuring SSa in plasma via LC–MS/MS.


The results showed that the absorption of SSa in Wistar rats was statistically superior to its absorption in Sprague Dawley rats based on pharmacokinetic parameters such as the area under the concentration–time curve (AUC0–t) and the peak concentration (Cmax). Pharmacokinetic studies of different doses of SSa in Wistar rats revealed that the systemic exposure of SSa, based on AUC values, increased disproportionately with dose, indicating that SSa exhibits non-dose-proportional pharmacokinetics. In addition, our studies showed that SSb2, a characteristic component of vinegar-baked Radix Bupleuri (VBRB), inhibits the absorption of SSa in rats.


The pharmacokinetic data for SSa obtained in this study will play an important role in attempts to better understand the fate of SSa in rats and to explore how these saikosaponins are likely to exert their pharmacological effects in vivo. In addition, further research is needed to elucidate the interactions of saikosaponins with metabolic enzymes and transporters in order to account for the phenomena observed in this study.


Compliance with Ethical Standards


This project was financially supported by the National Natural Science Foundation of China (no. 8157362), the Open Project Program of Guangxi Key Laboratory of Traditional Chinese Medicine Quality Standards (no. 201503), the Natural Research Foundation of Jiangsu Province (no. BK20161456), and the Qing Lan Project of Jiangsu Province (2017).

Conflict of interest

All the authors have no conflict of interest to declare.

Ethical approval

The animal experiments were approved by the ethical committee of China Pharmaceutical University and were carried out in accordance with the US guidelines for the care and use of laboratory animals.


  1. 1.
    Chang HM, But PP. Pharmacology and applications of Chinese materia medica. Singapore: World Scientific; 1986. p. 978–88.Google Scholar
  2. 2.
    Pan SL. Bupleurum species: scientific evaluation and clinical applications. Boca Raton: CRC Press; 2006.Google Scholar
  3. 3.
    Chen J, Duan M, Zhao Y, et al. Saikosaponin A inhibits influenza A virus replication and lung immunopathology. Oncotarget. 2015;6(40):42541–56.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Lee CH, Wang JD, Chen PC. Risk of liver injury associated with Chinese herbal products containing Radix Bupleuri in 639,779 patients with hepatitis B virus infection. PLoS One. 2011;6(1):e16064.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Xue DY, Liu GW, Chen YY. Effects of interferon-alpha combined with saikosaponin on serum T lymphocyte subgroups and hepatic cytokines in mice with immune hepatic injury. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012;32(1):68–71.PubMedGoogle Scholar
  6. 6.
    Yamamoto M, Kumagai A, Yamamura Y. Structure and actions of saikosaponins isolated from Bupleurum falcatum L. I. Anti-inflammatory action of saikosaponins. Arzneimittelforschung. 1975;25(7):1021–3.PubMedGoogle Scholar
  7. 7.
    Wang S, Zhang Y, Zhang Q, et al. Content decline of SERCA inhibitors saikosaponin a and d attenuates cardiotoxicity and hepatotoxicity of vinegar-baked Radix bupleuri. Environ Toxicol Pharmacol. 2017;52:129–37.PubMedGoogle Scholar
  8. 8.
    Wang X, Wang Q, Burczynski FJ, et al. Saikosaponin A of Bupleurum chinense (Chaihu) elevates bone morphogenetic protein 4 (BMP-4) during hepatic stellate cell activation. Phytomedicine. 2013;20(14):1330–5.PubMedGoogle Scholar
  9. 9.
    Afonina IS, Zhong Z, Karin M, et al. Limiting inflammation—the negative regulation of NF-kappaB and the NLRP3 inflammasome. Nat Immunol. 2017;18(8):861–9.PubMedGoogle Scholar
  10. 10.
    Chen MF, Huang CC, Liu PS, et al. Saikosaponin a and saikosaponin d inhibit proliferation and migratory activity of rat HSC-T6 cells. J Med Food. 2013;16(9):793–800.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Kang SJ, Lee YJ, Kang SG, et al. Caspase-4 is essential for saikosaponin a-induced apoptosis acting upstream of caspase-2 and gamma-H2AX in colon cancer cells. Oncotarget. 2017;8(59):100433–48.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Liu SJ, Ju WZ, Liu ZX, et al. Pharmacokinetic study of saikosaponin a in rat plasma by LC-ESI-MS. Chin Pharmacol Bull. 2009;25(10):1380–3.Google Scholar
  13. 13.
    Shimizu K, Amagaya S, Ogihara Y. Structural transformation of saikosaponins by gastric juice and intestinal flora. J Pharmacobiodyn. 1985;8(9):718–25.PubMedGoogle Scholar
  14. 14.
    Xu L, Song R, Tian JX, et al. Analysis of saikosaponins in rat plasma by anionic adducts-based liquid chromatography tandem mass spectrometry method. Biomed Chromatogr. 2012;26(7):808–15.PubMedGoogle Scholar
  15. 15.
    Zhang GS, Hu PY, Li DX, et al. Formulations, hemolytic and pharmacokinetic studies on saikosaponin a and saikosaponin d compound liposomes. Molecules. 2015;20(4):5889–907.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Jiang H, Jun LI, Shi RB, et al. Influence of processing on four saikosaponins in Radix Bupleuri. Chin Pharm J. 2009;44(21):1618–21.Google Scholar
  17. 17.
    Li ZY, Sun HM, Xing J, et al. Chemical and biological comparison of raw and vinegar-baked Radix Bupleuri. J Ethnopharmacol. 2015;165:20–8.PubMedGoogle Scholar
  18. 18.
    Darwish M, Kirby M, Robertson P Jr, et al. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clin Ther. 2006;28(5):707–14.PubMedGoogle Scholar
  19. 19.
    Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17(10):1278–83.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Wang LH, Wiznia AA, Rathore MH, et al. Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 2004;48(1):183–91.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Guan XF, Wang XY, Yan KJ, et al. UFLC-MS/MS determination and pharmacokinetic studies of six saikosaponins in rat plasma after oral administration of Bupleurum dropping pills. J Pharm Biomed Anal. 2016;124:288–93.PubMedGoogle Scholar
  22. 22.
    Lei T, Zhang D, Guo K, et al. Validated UPLC-MS/MS method for simultaneous quantification of eight saikosaponins in rat plasma: application to a comparative pharmacokinetic study in depression rats after oral administration of extracts of raw and vinegar-baked Bupleuri Radix. J Chromatogr B. 2017;1060:231–9.Google Scholar
  23. 23.
    Lu LL, Shu Y, Qian DW, et al. Identification of the metabolites of Sinisan extract in rat plasma, urine, feces and bile after intragastric administration. Yao Xue Xue Bao. 2011;46(11):1374–9.PubMedGoogle Scholar
  24. 24.
    Fujiwara K, Ogihara Y. Pharmacological effects of oral saikosaponin a may differ depending on conditions of the gastrointestinal tract. Life Sci. 1986;39(4):297–301.PubMedGoogle Scholar
  25. 25.
    Li YF, Su YM, Li TL. Material basis of Sini Powder with sedative-hypnotic effect. Chin Tradit Herb Drugs. 2012;43(7):1361–5.Google Scholar
  26. 26.
    Yang J, Huang DX, Lu XM, et al. Analysis on chemical constituents in Xiaochaihu Decoction and their in vivo metabolites in depressed rats. Chin Tradit Herb Drugs. 2012;43(9):1691–8.Google Scholar
  27. 27.
    Oltra-Noguera D, Mangas-Sanjuan V, González-Álvarez I, et al. Drug gastrointestinal absorption in rat: strain and gender differences. Eur J Pharm Sci. 2015;8:198–203.PubMedGoogle Scholar
  28. 28.
    Chieli E, Romiti N, Cervelli F, et al. Influence of rat strain on P-glycoprotein expression in cultured hepatocytes. Cell Biol Toxicol. 1994;10(3):163.PubMedGoogle Scholar
  29. 29.
    Gruzdkov AA, Yu V, Dmitrieva AS, Alekseeva AS, et al. Evaluation of glucose absorption level in the small intestine of different rat strains under natural conditions. J Evol Biochem Physiol. 2018;54(4):308–15.Google Scholar
  30. 30.
    Floreani M, Gabbia D, Barbierato M, et al. Differential inducing effect of benzo[a]pyrene, on gene expression and enzyme activity of cytochromes P450 1A1 and 1A2 in Sprague–Dawley and Wistar rats. Drug Metab Pharmacokinet. 2012;27(6):640–52.PubMedGoogle Scholar
  31. 31.
    Bruyère A, Declèves X, Bouzom F, et al. Development of an optimized procedure for the preparation of rat intestinal microsomes: comparison of hepatic and intestinal microsomal cytochrome P450 enzyme activities in two rat strains. Xenobiotica. 2009;39(1):11.Google Scholar
  32. 32.
    Dalziel JE, Fraser K, Young W, et al. Gastroparesis and lipid metabolism-associated dysbiosis in Wistar–Kyoto rats. Am J Physiol. 2017;33(1):G62–72.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Marques C, Meireles M, Norberto S, et al. High-fat diet-induced obesity rat model: a comparison between Wistar and Sprague–Dawley rat. Adipocyte. 2016;5(1):11–21.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Daniel SL, Hartman PA, Allison MJ. Microbial degradation of oxalate in the gastrointestinal tracts of rats. Appl Environ Microbiol. 1987;53(8):1793–7.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Ludden TM. Nonlinear pharmacokinetics: clinical implications. Clin Pharmacokinet. 1991;20(6):429–46.PubMedGoogle Scholar
  36. 36.
    Zhao Y, Wang YJ, Zhao RZ, et al. Vinegar amount in the process affected the components of vinegar-baked Radix Bupleuri and its hepatoprotective effect. BMC Complement Altern Med. 2016;16:346–52.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Chen R, Shen C, Xu Q, et al. The permeability characteristics and interaction of main components from Si-Ni-San in a MDCK epithelial cell monolayer model. Xenobiotica. 2017;Jul 26:1–26.Google Scholar
  38. 38.
    Chen Y, Wang J, Xin R, Tan X. Impact of saikosaponin on absorption and transport of paeoniflorin in Caco-2 cell model. Zhongguo Zhong Yao Za Zhi. 2012;37(12):1850–4.PubMedGoogle Scholar
  39. 39.
    Chen Y, Wang J, Yuan L, et al. Interaction of the main components from the traditional Chinese drug pair Chaihu-Shaoyao based on rat intestinal absorption. Molecules. 2011;16:9600–10.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Furuse M, Hirase T, Itoh M, et al. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol. 1993;123(6):1777–88.PubMedGoogle Scholar
  41. 41.
    Liu G, Tian Y, Li G, et al. Metabolism of saikosaponin a in rats: diverse oxidations on the aglycone moiety in liver and intestine in addition to hydrolysis of glycosidic bonds. Drug Metab Dispos. 2013;41:622–33.PubMedGoogle Scholar
  42. 42.
    Yu P, Qiu H, Wang M, et al. In vitro metabolism study of saikosaponin d and its derivatives in rat liver microsomes. Xenobiotica. 2017;47:11–9.PubMedGoogle Scholar
  43. 43.
    Yu T, Chen X, Wang Y, et al. Modulatory effects of extracts of vinegar-baked Radix Bupleuri and saikosaponins on the activity of cytochrome P450 enzymes in vitro. Xenobiotica. 2014;44:861–7.PubMedGoogle Scholar
  44. 44.
    Ye RP, Chen ZD. Saikosaponin A, an active glycoside from Radix Bupleuri, reverses P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cells and HepG2/ADM cells. Xenobiotica. 2016;47(2):1–9.Google Scholar
  45. 45.
    Feng L, Liu L, Zhao Y, et al. Saikosaponins A, C and D enhance liver-targeting effects of anticancer drugs by modulating drug transporters. Oncotarget. 2017;8(66):110092–102.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Zhao R, Liu L, Wang Y, et al. Vinegar-baked Radix Bupleuri modulates the cell membrane constituents and inhibits the P-gp activity in rat hepatocytes. BMC Complement Altern Med. 2014;14(1):1–7.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Key Laboratory of Drug Quality Control and PharmacovigilanceChina Pharmaceutical University, Ministry of EducationalNanjingChina
  2. 2.State Key Laboratory of Natural MedicineChina Pharmaceutical UniversityNanjingChina

Personalised recommendations